Pub Date : 2024-04-01DOI: 10.1097/bs9.0000000000000186
Weiru Liang, Chenmeng Liu, Jingliao Zhang, M. Yi, Yuli Cai, Aoli Zhang, Lipeng Liu, Li Zhang, Xiaojuan Chen, Yao Zou, Yumei Chen, Ye Guo, Yingchi Zhang, Xiaofan Zhu, Wenyu Yang
Juvenile myelomonocytic leukemia (JMML) is a disorder characterized by the simultaneous presence of myeloproliferative and myelodysplastic features, primarily affecting infants and young children. Due to the heterogeneous genetic background among patients, the current clinical and laboratory prognostic features are insufficient for accurately predicting outcomes. Thus, there is a pressing need to identify novel prognostic indicators. Red cell distribution width (RDW) is a critical parameter reflecting the variability in erythrocyte size. Recent studies have emphasized that elevated RDW serves as a valuable predictive marker for unfavorable outcomes across various diseases. However, the prognostic role of RDW in JMML remains unclear. Patients with JMML from our single-center cohort between January 2008 and December 2019 were included. Overall, 77 patients were eligible. Multivariate Cox proportional hazard models showed that patients with red cell distribution width coefficient of variation (RDW-CV) >17.35% at diagnosis were susceptible to much worse overall survival rate (hazard ratio [HR] = 5.22, confidence interval [CI] = 1.50–18.21, P = .010). Besides, the combination of RDW elevation and protein phosphatase non-receptor type 11 (PTPN11) mutation was likely to predict a subgroup with the worst outcomes in our cohort. RDW is an independent prognostic variable in JMML subjects. RDW may be regarded as an inexpensive biomarker to predict the clinical outcome in patients with JMML.
{"title":"The elevation of red blood cell distribution width is an independent prognostic factor for juvenile myelomonocytic leukemia","authors":"Weiru Liang, Chenmeng Liu, Jingliao Zhang, M. Yi, Yuli Cai, Aoli Zhang, Lipeng Liu, Li Zhang, Xiaojuan Chen, Yao Zou, Yumei Chen, Ye Guo, Yingchi Zhang, Xiaofan Zhu, Wenyu Yang","doi":"10.1097/bs9.0000000000000186","DOIUrl":"https://doi.org/10.1097/bs9.0000000000000186","url":null,"abstract":"Juvenile myelomonocytic leukemia (JMML) is a disorder characterized by the simultaneous presence of myeloproliferative and myelodysplastic features, primarily affecting infants and young children. Due to the heterogeneous genetic background among patients, the current clinical and laboratory prognostic features are insufficient for accurately predicting outcomes. Thus, there is a pressing need to identify novel prognostic indicators. Red cell distribution width (RDW) is a critical parameter reflecting the variability in erythrocyte size. Recent studies have emphasized that elevated RDW serves as a valuable predictive marker for unfavorable outcomes across various diseases. However, the prognostic role of RDW in JMML remains unclear. Patients with JMML from our single-center cohort between January 2008 and December 2019 were included. Overall, 77 patients were eligible. Multivariate Cox proportional hazard models showed that patients with red cell distribution width coefficient of variation (RDW-CV) >17.35% at diagnosis were susceptible to much worse overall survival rate (hazard ratio [HR] = 5.22, confidence interval [CI] = 1.50–18.21, P = .010). Besides, the combination of RDW elevation and protein phosphatase non-receptor type 11 (PTPN11) mutation was likely to predict a subgroup with the worst outcomes in our cohort. RDW is an independent prognostic variable in JMML subjects. RDW may be regarded as an inexpensive biomarker to predict the clinical outcome in patients with JMML.","PeriodicalId":9049,"journal":{"name":"Blood Science","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140782676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-07DOI: 10.1097/BS9.0000000000000185
In the original publication of our paper, “Sequential treatment escalation improves survival in patients with Waldenstrom mac-roglobulinemia,” published on Blood Science , 2024 Jan; 6(1): e00179, we have identified several errors that require correction. We apologize for any inconvenience caused and appreciate the opportunity to clarify the following: In Abstract, the post-relapse overall survival of patients in the escalation group and the non-escalation group (median, not reached vs. 50.7 months, respectively, P =0.039) was incorrectly reported. In Results of 3.6, the post-relapse overall survival of patients in the escalation group and the non-escalation group (median, not reached vs. 50.7 months, respectively, P =0.039) was incorrectly reported. Correction:Patients in the escalation group also had longer post-relapse overall survival compared with the non-escalation group (median, not reached vs. 50.7 months, respectively, P =0.039). The escalation group exhibited longer PFS2 (median, 50.4 months vs. 23.5 months, P <0.001) and post-relapse overall survival time (median, not reached vs. 50.7 months, respectively, P =0.039) than the non-escalation group (Figure 6A–B). These corrections do not significantly impact the overall findings and conclusions of the paper. We would like to assure readers that the corrected values do not alter the interpretations or validity of the research.
我们在《血液科学》（Blood Science , 2024 Jan; 6(1): e00179）上发表的论文《序贯治疗可提高瓦尔登斯特罗姆巨球蛋白血症患者的生存率》（Sequential treatment escalation improves survival in patients with Waldenstrom mac-roglobulinemia）中发现了几处需要更正的错误。我们对造成的不便深表歉意，并希望有机会澄清以下问题：摘要中，升级组和非升级组患者的复发后总生存期（中位数分别为未达到50.7个月和50.7个月，P =0.039）报告有误。在3.6的结果中，升级组和非升级组患者的复发后总生存期（中位数分别为未达到50.7个月和50.7个月，P =0.039）报告有误。更正：与非升级组相比，升级组患者的复发后总生存期也更长（中位数分别为未达50.7个月和50.7个月，P =0.039）。与非升级组相比，升级组的 PFS2（中位数 50.4 个月 vs. 23.5 个月，P <0.001）和复发后总生存期（中位数未达到 vs. 50.7 个月，P =0.039）更长（图 6A-B）。这些修正不会对论文的总体结果和结论产生重大影响。我们向读者保证，修正值不会改变研究的解释或有效性。
{"title":"Erratum: Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemia","authors":"","doi":"10.1097/BS9.0000000000000185","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000185","url":null,"abstract":"In the original publication of our paper, “Sequential treatment escalation improves survival in patients with Waldenstrom mac-roglobulinemia,” published on Blood Science , 2024 Jan; 6(1): e00179, we have identified several errors that require correction. We apologize for any inconvenience caused and appreciate the opportunity to clarify the following: In Abstract, the post-relapse overall survival of patients in the escalation group and the non-escalation group (median, not reached vs. 50.7 months, respectively, P =0.039) was incorrectly reported. In Results of 3.6, the post-relapse overall survival of patients in the escalation group and the non-escalation group (median, not reached vs. 50.7 months, respectively, P =0.039) was incorrectly reported. Correction:Patients in the escalation group also had longer post-relapse overall survival compared with the non-escalation group (median, not reached vs. 50.7 months, respectively, P =0.039). The escalation group exhibited longer PFS2 (median, 50.4 months vs. 23.5 months, P <0.001) and post-relapse overall survival time (median, not reached vs. 50.7 months, respectively, P =0.039) than the non-escalation group (Figure 6A–B). These corrections do not significantly impact the overall findings and conclusions of the paper. We would like to assure readers that the corrected values do not alter the interpretations or validity of the research.","PeriodicalId":9049,"journal":{"name":"Blood Science","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140076984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：